Agents of Change: Improving the Collaboration Among CAR T Center Experts and Community-Based Clinicians for Improved Care of DLBCL Patients - Baseline Assessment
This assessment will provide a baseline measure of your knowledge of CAR T-cell therapy and management for DLBCL, including, barriers, and challenges for treatment.
Gilles Salles, MD, PhD
Chief, Lymphoma Service
Lymphoma Specialist and Cellular Therapist
Memorial Sloan Kettering Cancer Center
New York, NY
Gilles Salles, MD, PhD, was appointed Chief of the Lymphoma Service at MSK in 2020. He previously held the position of Professor of Hematology and Medicine at the University of Lyon and Head of the Department of Hematology at the Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, in Pierre-Bénite, France.
Dr. Salles obtained his medical degree and his doctoral degree in differentiation, genetics, and immunology from the Université Claude Bernard Lyon-1. He completed further training as a researcher in oncology at the Dana-Farber Cancer Institute of Harvard Medical School.
Throughout his career, Dr. Salles has been especially interested in the clinical and biological study of lymphoma. The primary focus of his work is on the description and validation of prognostic factors and clinical trials in indolent lymphomas. His team has also examined several aspects of lymphoma biology, including T-cell and B-cell lymphoma models, signaling, and genomic biology of indolent lymphomas.
Dr. Salles has been involved in the investigation and development of new therapeutic agents such as targeted therapies, new monoclonal antibodies, and other immunotherapies in the field. He has led large international studies evaluating treatment options in patients with follicular lymphoma.
A member of several international societies, including the American Society of Hematology, Dr. Salles is also the author of more than 600 publications, including articles in international peer-reviewed journals such as The New England Journal of Medicine, Blood, The Journal of Clinical Oncology, The Lancet, Haematologica, Lancet Oncology, and Leukemia and Lymphoma.
1.
Assess the latest efficacy and safety data of available CD19-directed CAR T-cell therapies for relapsed or refractory DLBCL.
2.
Examine patient eligibility and logistical considerations to optimize the timely referral and integration of CAR T-cell therapy for patients with DLBCL.
3.
Apply strategies for the multidisciplinary care team to appropriately monitor and manage adverse events in patients with DLBCL throughout the CAR-T journey.
4.
Integrate shared decision-making and patient-centered strategies for patients with DLBCL throughout their CAR T-cell therapy journey.
